Universe · entity
Atle Fund Management AB
Institutional manager (13F) · CIK 1381843
13F holdings · as of 2026-03-31 · top 39 · reported portfolio $310M
| # | Issuer | Value | Shares |
|---|---|---|---|
| 1 | ELI LILLY & CO | $27M | 39,722 |
| 2 | MERCK & CO. INC | $23M | 33,853 |
| 3 | THERMO FISHER SCIENTIFIC CORP | $14M | 22,986 |
| 4 | BEONE MEDICINES LTD-ADR | $12M | 41,717 |
| 5 | JOHNSON & JOHNSON | $12M | 92,377 |
| 6 | BRIDGEBIO PHARMA INC | $12M | 111,363 |
| 7 | VERTEX PHARMACEUTICALS INC | $11M | 22,984 |
| 8 | ABBVIE INC | $10M | 108,181 |
| 9 | STRYKER CORPORATION | $10M | 26,835 |
| 10 | INTUITIVE SURGICAL INC | $9M | 70,851 |
| 11 | IONIS PHARMACEUTICALS INC | $9M | 27,873 |
| 12 | MIRUM PHARMACEUTICALS INC | $9M | 195,768 |
| 13 | CVS HEALTH CORP | $9M | 23,773 |
| 14 | REVOLUTION MEDICINES INC | $9M | 617,245 |
| 15 | BOSTON SCIENTIFIC CORP | $9M | 40,432 |
| 16 | AMGEN INC | $9M | 21,903 |
| 17 | EDWARDS LIFESCIENCES CORP | $8M | 106,518 |
| 18 | ALKERMES PLC | $8M | 242,473 |
| 19 | INCYTE CORP | $8M | 50,796 |
| 20 | NEUROCRINE BIOSCIENCES INC | $8M | 89,685 |
| 21 | GILEAD SCIENCES INC | $7M | 47,967 |
| 22 | KRYSTAL BIOTECH, INC | $7M | 37,579 |
| 23 | CENCORA INC | $7M | 23,470 |
| 24 | IRHYTHM TECHNOLOGIES INC | $6M | 22,322 |
| 25 | INSMED INC | $6M | 97,438 |
| 26 | NEWAMSTERDAM PHARMA CO NV | $6M | 94,796 |
| 27 | CELCUITY INC | $5M | 141,296 |
| 28 | ABIVAX SA | $5M | 31,590 |
| 29 | CARDINAL HEALTH INC | $5M | 108,682 |
| 30 | IDEAYA BIOSCIENCES INC | $4M | 31,133 |
| 31 | TANGO THERAPEUTICS INC | $4M | 29,915 |
| 32 | SPYRE THERAPEUTICS INC | $3M | 62,735 |
| 33 | DISC MEDICINE INC | $3M | 107,255 |
| 34 | COMPASS THERAPEUTICS INC | $3M | 41,831 |
| 35 | UNIVERSAL HEALTH SERVICES INC | $3M | 14,636 |
| 36 | DEXCOM INC | $3M | 584,332 |
| 37 | BICARA THERAPEUTICS INC | $2M | 1,169,634 |
| 38 | SOLENO THERAPEUTICS INC | $2M | 90,184 |
| 39 | PYXIS ONCOLOGY INC | $2M | 197,036 |
Source: sec_edgar_13f · public regulatory · retrieved 2026-06-29. Public SEC data; no contact information.